IV Artesunate

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, RESnTEC, Institute of Research, Novartis Pharma AG

Conditions

MalariaSevere Malaria

Phase 2

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

CompletedNCT04675931

Novartis PharmaceuticalsSevere Malaria

Start: 2022-03-07End: 2025-08-20Updated: 2025-12-22

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria - KAE609B12201(KARISMA)

RecruitingPACTR202102626263606

Novartis Pharma AGMalaria

Start: 2021-06-28Target: 252Updated: 2026-01-27

Unknown Phase

Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study

CompletedNCT06472258

RESnTEC, Institute of ResearchMalaria

Start: 2023-03-01End: 2023-06-30Updated: 2024-06-26

Related Papers

SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART).

2023-01-014 citations